PHYCHEM TECHNOLOGIES LIMITED
Upcoming31 Aug – 2 Sep 2026
Updated 2026-08-28 (IST)
What PHYCHEM TECHNOLOGIES LIMITED does
We are engaged in the manufacturing of rotational molding (roto molding) compounds, which serve as a key raw material for producing a wide range of hollow plastic products through the rotational molding process. Our product portfolio primarily comprises customized polyethylene-based compounds, formulated using Linear Low-Density Polyethylene (LLDPE), High-Density Polyethylene (HDPE), and other specialty additives.
PHYCHEM TECHNOLOGIES LIMITED financials
Rs crore · AnnualLatest year highlighted in green. Sparklines show the trend.
| 2024 | 2025 | 2026 | ||
|---|---|---|---|---|
| Sales | 47 | 50 | 56 | |
| Operating Profit | — | — | — | |
| OPM % | — | — | — | |
| Net Profit | — | — | — | |
| Total Debt | 6 | 5 | 6 |
PHYCHEM TECHNOLOGIES LIMITED IPO offer structure
Fresh issue: ₹15 cr
The offer-for-sale component is not stated in what we extracted from the offer document, so the full issue size and the split between the two are unknown. This figure is the fresh issue alone, not the total raise. Fresh issue proceeds go to the company; OFS proceeds go to selling shareholders.
Issue size and split come from a public aggregator rather than the exchange, cross-checked against a second one. The offer document states the offer-for-sale as a share count against a blank amount, so it cannot be read from the document itself.
Use of proceeds- Repayment in full or in part, of certain of our outstanding borrowings: ₹3 cr
- Funding the capital expenditure towards procurement of plant and machinery: ₹5 cr
- Funding to meet working capital requirements: ₹3 cr
- General Corporate Purpose
PHYCHEM TECHNOLOGIES LIMITED promoters and holding
- Umakant Nivrutti Savadekar: Chairman and Managing Director
- Ulka Umakant Savadekar: Whole-Time Director and CFO
- Nivrutti Sonu Savdekar: Non-executive Director
- Vijaya Nivrutti Savdekar: Non-executive Director
PHYCHEM TECHNOLOGIES LIMITED strengths and risks
Company-stated strengths and disclosed risk factors from the offer document.
- Wide range of products finding diverse application in roto moulding industry. (p.111)
- Long standing relationships with diversified customers across geographies. (p.112)
- In-house manufacturing facility with equipped machines and processes. (p.113)
- Focus on Quality, Environment, Health and Safety. (p.113)
- Experienced Promoters and Management with extensive domain knowledge. (p.114)
- Our business is dependent and will continue to depend on our manufacturing facility, and we are subject to certain risks in our manufacturing process. (p.24)
- We derive a significant part of our revenue from major customers and we do not have long term agreements with any of these customers. (p.25)
- We are heavily reliant on few suppliers for the supply of our raw materials, with our single largest supplier contributing to more than 50% of our purchases during the last 3 financial years. (p.25)
- We derive a portion of our revenues from exports and are subject to risk of international trade. (p.26)
- Exchange rate fluctuations may adversely affect our results of operations as our sales from exports and purchases from imports are denominated in foreign currencies. (p.27)
PHYCHEM TECHNOLOGIES LIMITED market and competition
Our competition varies by market, geographic areas and type of product. As a result, to remain competitive in our markets, we must continuously strive to reduce our costs of production, transportation and distribution and improve our operating efficiencies. We compete with various companies in organised and unorganised structure.
PHYCHEM TECHNOLOGIES LIMITED outlook, as the document states it
We seek to leverage our capabilities, including our manufacturing facilities and quality control practices, to further expand our product portfolio in the existing segments and also enter new product development. We intend to continue to focus on our ability to customize our products according to the specific requirements of our customers and broaden our portfolio and focus on sustainable solutions. We also plan to strengthen our market domestically to other Indian states and expand our exports and diversify geographically to mitigate risks.
Never miss an IPO like this
Every upcoming IPO analysed: subscription, GMP and a DRHP breakdown, in your inbox, free. One email when each one opens.
PHYCHEM TECHNOLOGIES LIMITED IPO: common questions
When does the PHYCHEM TECHNOLOGIES LIMITED IPO open and close?
The PHYCHEM TECHNOLOGIES LIMITED IPO is open from 31 Aug 2026 to 2 Sep 2026.
What is the PHYCHEM TECHNOLOGIES LIMITED IPO price band?
The price band is ₹51–₹54 per share.
What is the lot size and minimum investment for the PHYCHEM TECHNOLOGIES LIMITED IPO?
One lot is 2000 shares, and a retail application must be at least one lot. That is about ₹2,16,000 at the upper end of the band. An HNI application starts above Rs 2 lakh, so the minimum is higher for that category.
When are the PHYCHEM TECHNOLOGIES LIMITED IPO allotment and listing dates?
Not published yet. Derived from the close date on the usual timetable: allotment around 3 Sep 2026, refund/unblock around 4 Sep 2026 and listing around 7 Sep 2026. Treat these as estimates until the exchange confirms them.
How do I apply for the PHYCHEM TECHNOLOGIES LIMITED IPO?
Through any broker app or your bank's net banking, using a demat account and a PAN. You bid in lots at a price inside the band, or at cut-off. The money is blocked in your account, not debited, until allotment. One application per PAN. Bidding opens 31 Aug 2026. We do not recommend brokers and carry no broker links. How to apply, start to finish →
Sources & method
Subscription and issue data come from the NSE and BSE exchange feeds, with the third-party aggregator, clearly labelled, where an exchange feed is unreachable. DRHP analysis is extracted from the offer document itself, every figure cited to its page. Each figure on the page carries its source and its timestamp.
Grey-market premium (GMP) is unregulated.
Every GMP figure is a self-reported grey-market estimate. No exchange, regulator or clearing body records or audits it, and there is no settlement guarantee or recourse. Shown for context only; never decide on GMP alone. New to GMP? The 30-second explainer → Has GMP actually been right? →
How often do these actually open above the issue price?
Of the 701 SME IPOs that have listed on the NSE since 2016, 557 (79%) opened above their issue price, at a median of +11%. That is the segment's own record, not a forecast for this issue.